Loading

Neuroene Therapeutics

May 06, 2024
Session
Neuroene is developing mitochondrial-protective small molecules for epilepsy, Parkinson's and mitochondrial diseases. Our lead clinical candidate has FDA Orphan Drug Designation for Dravet syndrome, a rare childhood epilepsy with striking efficacy as a monotherapy in many animal seizure models, and works as an adjunct with additive antiseizure activity with no adverse drug-drug effects so far. Our candidate is well-tolerated, brain-penetrating, fast-acting and targets a new mechanism of action (mitochondrial protection) that is differentiated and complementary to current antiseizure medications. We seek $10M for IND-enabling studies and Phase I trials. We previously won the 2022 BioHealth Capital Region pitch competition.
View all SUS 2024

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS